Significant cost savings achieved by in-sourcing urine drug testing for monitoring medication compliance in pain management

Clinica Chimica Acta

Volumn 422, Issue , 2013, Pages 10-14

  Melanson, Stacy E F ^a   Tanasijevic, Milenko J ^a   Snyder, Marion L ^b   Darragh, Alicia ^a   Quade, Cathleen ^a   Jarolim, Petr ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

In sourcing; LC MS MS; Pain management; Send out costs; Toxicology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE DERIVATIVE; ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID; COCAINE; DEXTROPROPOXYPHENE; FENTANYL; METHADONE; MORPHINE 6 ACETATE; NARCOTIC ANALGESIC AGENT; PHENCYCLIDINE; TRAMADOL;

ACCURACY; ANALGESIA; ARTICLE; BUDGET; COST BENEFIT ANALYSIS; COST CONTROL; HEALTH CARE COST; HUMAN; IMMUNOASSAY; LABORATORY TEST; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; URINE DRUG TESTING;

BUPRENORPHINE; CHROMATOGRAPHY, LIQUID; COST SAVINGS; DRUG MONITORING; FENTANYL; HUMANS; MEDICATION ADHERENCE; MORPHINE DERIVATIVES; PAIN MANAGEMENT; TANDEM MASS SPECTROMETRY; TRAMADOL; URINALYSIS;

EID: 84876716488     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.03.010     Document Type: Article

References (20)

1. Langman L., Bechtel L., Holstege C.P. Clinical toxicology. Tietz textbook of clinical chemistry and molecular diagnostics 2012, 1109-1129. Elsevier Saunders, St. Louis. C.A. Burtis, E.R. Ashwood, D.E. Bruns (Eds.).
2. Trescot A.M., Helm S., Hansen H., Benyamin R., Glaser S.E., Adlaka R., et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008, 11:S5-S62.
3. Bhamb B., Brown D., Hariharan J., Anderson J., Balousek S., Fleming M.F. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006, 22:1859-1865.
4. Heit H.A., Gourlay D.L. Urine drug testing in pain medicine. J Pain Symptom Manage 2004, 27:260-267.
5. Ives T.J., Chelminski P.R., Hammett-Stabler C.A., Malone R.M., Perhac J.S., Potisek N.M., et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006, 6:46.
6. Katz N., Fanciullo G.J. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002, 18:S76-S82.
7. Katz N.P., Sherburne S., Beach M., Rose R.J., Vielguth J., Bradley J., et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003, 97:1097-1102.
8. Manchikanti L., Cash K.A., Damron K.S., Manchukonda R., Pampati V., McManus C.D. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician 2006, 9:215-225.
9. Manchikanti L., Manchukonda R., Pampati V., Damron K.S., Brandon D.E., Cash K.A., et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?. Pain Physician 2006, 9:123-129.
10. Michna E., Jamison R.N., Pham L.D., Ross E.L., Janfaza D., Nedeljkovic S.S., et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain 2007, 23:173-179.
11. Trescot A.M., Boswell M.V., Atluri S.L., Hansen H.C., Deer T.R., Abdi S., et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006, 9:1-39.
12. Manchikanti L., Atluri S., Trescot A.M., Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician 2008, 11:S155-S180.
13. Melanson S.E., Kredlow M.I., Jarolim P. Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective. Clin Chem Lab Med 2009, 47:971-976.
14. Cone E.J., Caplan Y.H., Black D.L., Robert T., Moser F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol 2008, 32:530-543.
15. Nafziger A.N., Bertino J.S. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain 2009, 25:73-79.
16. Magnani B., Kwong T. Urine drug testing for pain management. Clin Lab Med 2012, 32:379-390.
17. Melanson S.E. The utility of immunoassays for urine drug testing. Clin Lab Med 2012, 32:429-447.
18. Melanson S.E., Snyder M.L., Jarolim P., Flood J.G. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse. J Anal Toxicol 2012, 36:201-206.
19. Snyder M.L., Jarolim P., Melanson S.E. A new automated urine fentanyl immunoassay: technical performance and clinical utility for monitoring fentanyl compliance. Clin Chim Acta 2011, 412:946-951.
20. Langman L., Bowers L.D., Collins J.A., Hammett-Stabler C.A., LeBeau M.A. C43-A2 gas chromatography/mass spectrometry confirmation of drugs 2010, Clinical and Laboratory Standards Institute.